Tag
Revolution Medicines announced Phase 3 data showing daraxonrasib extended median survival to 13.2 months in advanced pancreatic adenocarcinoma versus 6.7 months on standard chemotherapy. The near-doubling of survival in one of oncology's hardest-to-treat cancers positions Revolution for an FDA approval filing. No
Allogene Therapeutics CMO Zach Roberts presented new study results for the company's off-the-shelf CAR-T therapy targeting B-cell lymphoma, an allogeneic approach that bypasses patient-specific cell manufacturing. If validated further, the model could lower treatment costs and shorten time to therapy versus
A Nature-published genomics-guided trial finds off-label cancer treatments can be effective when matched to tumor genetic profiles. The findings could broaden prescribing options for patients beyond standard approved indications, pressing regulators and insurers to revisit reimbursement frameworks. The study appeared o
Revolution Medicines shares jumped sharply after clinical trial results for its cancer therapy were characterized as unprecedented. The data point carries outsized weight because RAS-targeted oncology is a historically resistant space where efficacy breakthroughs drive significant pipeline revaluation. Investor attenti
Tag
Revolution Medicines announced Phase 3 data showing daraxonrasib extended median survival to 13.2 months in advanced pancreatic adenocarcinoma versus 6.7 months on standard chemotherapy. The near-doubling of survival in one of oncology's hardest-to-treat cancers positions Revolution for an FDA approval filing. No
2mo ago · 1 min · Technology
Allogene Therapeutics CMO Zach Roberts presented new study results for the company's off-the-shelf CAR-T therapy targeting B-cell lymphoma, an allogeneic approach that bypasses patient-specific cell manufacturing. If validated further, the model could lower treatment costs and shorten time to therapy versus
2mo ago · 1 min · Technology
A Nature-published genomics-guided trial finds off-label cancer treatments can be effective when matched to tumor genetic profiles. The findings could broaden prescribing options for patients beyond standard approved indications, pressing regulators and insurers to revisit reimbursement frameworks. The study appeared o
2mo ago · 1 min · Technology
Revolution Medicines shares jumped sharply after clinical trial results for its cancer therapy were characterized as unprecedented. The data point carries outsized weight because RAS-targeted oncology is a historically resistant space where efficacy breakthroughs drive significant pipeline revaluation. Investor attenti
2mo ago · 1 min · Markets
— End of feed —